Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...
Merck’s $8 Billion Cancer Vaccine Faces First US Trial
Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify Cryptigen™ Tumor-Specific Antigens
Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...
FierceBiotech3d
Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner
Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 ...
FierceBiotech3d
Merck pens $300M-per-product collab with Epitopea to locate 'hidden' tumor antigens
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...